Genetic risk factors for type 2 diabetes mellitus and response to sulfonylurea treatment

Pharmacogenetics and Genomics

Volumn 21, Issue 8, 2011, Pages 461-468

  Swen, Jesse J ^a   Guchelaar, Henk Jan ^a   Baak Pablo, Renée F ^a   Assendelft, Willem J J ^a   Wessels, Judith A M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

glibenclamide; gliclazide; glimepiride; pharmacogenetics; sulfonylureas; tolbutamide; type 2 diabetes mellitus

Indexed keywords

ADAMTS9 PROTEIN; CDC123 PROTEIN; CDKAL1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; FTO PROTEIN; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; HEPATOCYTE NUCLEAR FACTOR 1BETA; HHEX PROTEIN; IGF2BP2 PROTEIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; JAZF1 PROTEIN; KCNQ1 PROTEIN; LGR5 PROTEIN; METALLOPROTEINASE; METFORMIN; MTNR1B PROTEIN; NOTCH2 RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN; SLC30A8 PROTEIN; THADA PROTEIN; TOLBUTAMIDE; TRANSCRIPTION FACTOR 7 LIKE 2; UNCLASSIFIED DRUG; WFS1 PROTEIN;

ADULT; AGE; ALLELE; ARTICLE; DRUG RESPONSE; FEMALE; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOGENETICS; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

SUS;

EID: 79960834947     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283478173     Document Type: Article

References (47)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27:1047-1053. (Pubitemid 38579764)
2. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65:385-411. (Pubitemid 40227460)
3. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131:281-303.
4. Pearson ER. Pharmacogenetics and future strategies in treating hyperglycaemia in diabetes. Front Biosci 2009; 14:4348-4362.
5. Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992; 15:737-754.
6. Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C, Sparso T, Holmkvist J, Marchand M, et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet 2009; 41:89-94.
7. Steinthorsdottir V, Thorleifsson G, Reynisdottir I, Benediktsson R, Jonsdottir T, Walters GB, et al. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet 2007; 39:770-775. (Pubitemid 46848592)
8. Zeggini E,Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007; 316:1336-1341. (Pubitemid 46871654)
9. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, et al. Metaanalysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 2008; 40:638-645. (Pubitemid 351601209)
10. Yasuda K, Miyake K, Horikawa Y, Hara K, Osawa H, Furuta H, et al. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet 2008; 40:1092-1097.
11. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007; 316:1341-1345. (Pubitemid 46871655)
12. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007; 316:1331-1336. (Pubitemid 46871653)
13. Wellcome Trust Case Control Consortium. Genome-wide association study of 14 000 cases of seven common diseases and 3000 shared controls. Nature 2007; 447:661-678.
14. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, et al. A genomewide association study identifies novel risk loci for type 2 diabetes. Nature 2007; 445:881-885.
15. Winckler W,Weedon MN, Graham RR, McCarroll SA, Purcell S, Almgren P, et al. Evaluation of common variants in the six known maturity-onset diabetes of the young (MODY) genes for association with type 2 diabetes. Diabetes 2007; 56:685-693. (Pubitemid 46348464)
16. Lyssenko V, Nagorny CL, Erdos MR, Wierup N, Jonsson A, Spegel P, et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet 2009; 41:82-88.
17. Unoki H, Takahashi A, Kawaguchi T, Hara K, Horikoshi M, Andersen G, et al. SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet 2008; 40:1098-1102.
18. Cornelis MC, Qi L, Zhang C, Kraft P, Manson J, Cai T, et al. Joint effects of common genetic variants on the risk for type 2 diabetes in US men and women of European ancestry. Ann Intern Med 2009; 150:541-550.
19. Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008; 359:2220-2232.
20. Lango H, Palmer CN, Morris AD, Zeggini E, Hattersley AT, McCarthy MI, et al. Assessing the combined impact of 18 common genetic variants of modest effect sizes on type 2 diabetes risk. Diabetes 2008; 57:3129-3135.
21. Talmud PJ, Hingorani AD, Cooper JA, Marmot MG, Brunner EJ, Kumari M, et al. Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: whitehall II prospective cohort study. BMJ 2010; 340:b4838.
22. Van Hoek M, Dehghan A, Witteman JC, Van Duijn CM, Uitterlinden AG, Oostra BA, et al. Predicting type 2 diabetes based on polymorphisms from genome-wide association studies: a population-based study. Diabetes 2008; 57:3122-3128.
23. Meigs JB, Shrader P, Sullivan LM, McAteer JB, Fox CS, Dupuis J, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med 2008; 359:2208-2219.
24. Sparso T, Grarup N, Andreasen C, Albrechtsen A, Holmkvist J, Andersen G, et al. Combined analysis of 19 common validated type 2 diabetes susceptibility gene variants shows moderate discriminative value and no evidence of gene-gene interaction. Diabetologia 2009; 52:1308-1314.
25. Rutten GEHM, De Grauw WJC, Nijpels G, Goudswaard AN, Uitewaal PJM, Van Der Does FEE, et al. NHG-standard diabetes mellitus type 2. Huisarts en Wetenschap 2006; 49:137-152.
26. Swen JJ, Wessels JA, Krabben A, Assendelft WJ, Guchelaar HJ. Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with type 2 diabetes mellitus. Pharmacogenomics 2010; 11:1517-1523.
27. Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmoller J. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet 2005; 44:1209-1225. (Pubitemid 41832564)
28. Holstein A, Plaschke A, Ptak M, Egberts EH, El Din J, Brockmoller J, et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol 2005; 60:103-106. (Pubitemid 40942788)
29. Ragia G, Petridis I, Tavridou A, Christakidis D, Manolopoulos VG. Presence of CYP2C9*3 allele increases risk for hypoglycemia in type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics 2009; 10:1781-1787.
30. Becker ML, Visser LE, Trienekens PH, Hofman A, Van Schaik RH, Stricker BH. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin Pharmacol Ther 2008; 83:288-292.
31. Zhou K, Donnelly L, Burch L, Tavendale R, Doney AS, Leese G, et al. Loss-offunction CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. Clin Pharmacol Ther 2009; 87:52-56.
32. Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 2003; 362:1275-1281. (Pubitemid 37324255)
33. Sagen JV, Raeder H, Hathout E, Shehadeh N, Gudmundsson K, Baevre H, et al. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes 2004; 53:2713-2718. (Pubitemid 39299284)
34. Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, Larkin B, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006; 355:467-477. (Pubitemid 44162274)
35. Becker ML, Aarnoudse AJ, Newton-Cheh C, Hofman A, Witteman JC, Uitterlinden AG, et al. Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea. Pharmacogenet Genomics 2008; 18:591-597.
36. Bozkurt O, De Boer A, Grobbee DE, Heerdink ER, Burger H, Klungel OH. Pharmacogenetics of glucose-lowering drug treatment: a systematic review. Mol Diagn Ther 2007; 11:291-302. (Pubitemid 350014793)
37. Xu H, Murray M, McLachlan AJ. Influence of genetic polymorphisms on the pharmacokinetics and pharmaco-dynamics of sulfonylurea drugs. Curr Drug Metab 2009; 10:643-658.
38. Aquilante CL. Sulfonylurea pharmacogenomics in type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Rev Cardiovasc Ther 2010; 8:359-372.
39. Sesti G, Laratta E, Cardellini M, Andreozzi F, Del Guerra S, Irace C, et al. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 50-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91:2334-2339. (Pubitemid 43855025)
40. Gloyn AL, Hashim Y, Ashcroft SJ, Ashfield R, Wiltshire S, Turner RC. Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53). Diabet Med 2001; 18:206-212. (Pubitemid 32397858)
41. Holstein A, Hahn M, Stumvoll M, Kovacs P. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes. Horm Metab Res 2009; 41:387-390.
42. Pearson ER, Donnelly LA, Kimber C, Whitley A, Doney AS, McCarthy MI, et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 2007; 56:2178-2182. (Pubitemid 47195841)
43. Van den Berg MJ, De Bakker DH, Spreeuwenberg P, Westert GP, Braspenning JC, Van der ZJ, et al. Labour intensity of guidelines may have a greater effect on adherence than GPs' workload. BMC Fam Pract 2009; 10:74.
44. Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M, et al. Pharmacogenetic prediction of clozapine response. Lancet 2000; 355:1615-1616. (Pubitemid 30240510)
45. Inayama Y, Yoneda H, Sakai T, Ishida T, Nonomura Y, Kono Y, et al. Positive association between a DNA sequence variant in the serotonin 2A receptor gene and schizophrenia. Am J Med Genet 1996; 67:103-105.
46. Holloway JW, Dunbar PR, Riley GA, Sawyer GM, Fitzharris PF, Pearce N, et al. Association of beta-2-adrenergic receptor polymorphisms with severe asthma. Clin Exp Allergy 2000; 30:1097-1103. (Pubitemid 30619762)
47. Lipworth BJ, Dempsey OJ, Aziz I. Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism. Chest 2000; 118:321-328. (Pubitemid 30637794)